Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
March 15 2023 - 4:01PM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
clinical-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic rare diseases of the central nervous system (CNS), today
announced that it will report its financial results for the fourth
quarter and full-year ended December 31, 2022, and host a corporate
update conference call and webcast on Tuesday, March 28, 2023, at
4:30 PM Eastern Time.
Conference
Call Details |
Tuesday,
March 28, at 4:30 PM Eastern Time / 3:30 PM Central
Time |
Toll Free: |
877-407-0792 |
International: |
201-689-8263 |
Conference ID: |
13736479 |
Webcast: |
https://ir.tayshagtx.com/news-events/events-presentations |
|
|
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program. Together, we leverage our fully integrated platform—an
engine for potential new cures—with a goal of dramatically
improving patients’ lives. More information is available at
www.tayshagtx.com.
Company Contact:Kimberly Lee, D.O. Chief
Corporate Affairs OfficerTaysha Gene
Therapiesklee@tayshagtx.com
Media Contact:Carolyn HawleyEvoke
Canalecarolyn.hawley@evokegroup.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024